| Phase 2, randomized, open-label, controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe refractory idiopathic inflammatory myopathies |
Ongoing |
Rapcabtagene autoleucel (YTB323) |
2 |
CYTB323L12201 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| EASi-HF reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% |
Ongoing |
Vicadrostat (BI 690517)/ Jardiance (BI 10773) |
3 |
1378-0018 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh),King Fahad specialist hospital,(Dammam) King Abdulaziz Hospital NG (Al-Ahsa), Imam Abdulrahman Bin Faisal University (Khobar) |
| A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis |
Ongoing |
Survodutide |
2 |
1404-0044 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone with Background Dapagliflozin in Subjects with Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM) |
Ongoing |
Apabetalone |
2 |
RVX222-CS-025 |
King Abdulaziz Medical City NG (Al-Ahsa), King Abdulaziz Medical City NG (Riyadh) |
| An Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers |
Ongoing |
Durvalumab |
4 |
D419CR00035 |
King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors |
Ongoing |
Marstacimab |
3 |
B7841007 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
| Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial) |
Ongoing |
Sodium Chloride / Lactated Ringers |
4 |
FLASC01 |
King Fahad University Hospital (Al-Khobar) |
| A Phase 3, Randomized, Double-Blind,Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease |
Ongoing |
Tulisokibart |
3 |
NCT0643080 |
King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Hospital NG (Riyadh), King Saud University Medical City (Riyadh), King Abdullah Medical City Specialist Hospital (Makkah) |
| Prospective multi-country, real-world, multi-arm study of treatment PErsistence with RISankizumab in Psoriatic Arthritis |
Ongoing |
Risankizumab (Skyrizi®) |
4 |
P24-390 |
King Fahad Medical City (Riyadh) |
| An Open-label, Single-arm Study to Evaluate the Safety and Tolerability of Intravenous Difelikefalin in Adolescents Aged 12 to 17 Years on Haemodialysis with Moderate-to-Severe Pruritus |
Ongoing |
Difelikefalin |
2 |
KOR-PED-202 |
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Jeddah),King Faisal Specialist Hospital and Research Center (Jeddah) |
